Print

AstraZeneca PLC (AZN) Not Done With Cost Cuts  
11/12/2010 7:48:24 AM

NEW YORK (Reuters) - AstraZeneca Plc (AZN.L), facing patent expirations on its top-selling medicines, sees room for more cost cuts in marketing, sales and other areas to shore up profits, its chief executive said on Wednesday.
//-->